Chronic Obstructive Pulmonary Disease Clinical Trial
— MINDNUTOfficial title:
Multidimensional INDividualized NUTritional Therapy for Individuals With Severe Chronic Obstructive Pulmonary Disease
NCT number | NCT04873856 |
Other study ID # | MINDNUT NOH |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 21, 2021 |
Est. completion date | June 14, 2023 |
Verified date | December 2023 |
Source | Nordsjaellands Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Individuals with severe chronic pulmonary disease often life isolated with a high burden of symptoms. Nutritional risk and low quality of life are common, and both associated with increased societal cost and poor prognosis. COPD is a complex and progressive disease with changing clinical states that influences nutritional status and quality of life in different ways. The primary aim is to improve quality of life for individuals with severe COPD. 120 individuals are recruited from the outpatient clinic at Nordsjællands Hospital in Denmark to a randomized controlled trial with two parallel groups (intervention and control). The intervention will last for 3 months comprising four elements including nutritional plan, regular contact, informal caregiver/friendly reminder and a weight dairy. We expect that the intervention will improve quality of life, nutritional status and prognosis.
Status | Completed |
Enrollment | 87 |
Est. completion date | June 14, 2023 |
Est. primary completion date | June 14, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years and older |
Eligibility | Inclusion Criteria: - = 35 years - Severe COPD defined as GOLD grade 2 group B or D OR GOLD grade 3 and 4 group ABCD - Able to eat orally - Live in own home - Speak Danish or English - Undernourished OR at risk of undernutrition defined as BMI = 21 kg/m2 if < 70 years and BMI <22 kg/m2 if =70 years OR BMI 21-25 kg/m2 plus nutritional risk (nutritional risk screening score =3) if <70 years and BMI 22-25 kg/m2 plus nutritional risk if =70 years - Stable phase CHANGE: Undernourished OR at risk of undernutrition (a maximum BMI of 25 kg/m2) determined by Nutritional Risk Screening 2002 or Mini Nutritional Assessment Short Form according to the protocol published in Trials. Exclusion Criteria: - Active solid cancer" defined as cancer diagnosed within the previous six months, recurrent, regionally advanced, or metastatic cancer, cancer for which treatment had been administered within six months or hematological cancer that is not in complete remission - Unable to sign informed consent e.g. due to severe dementia. - Severe chronic renal failure defined as estimated glomerular filtration rate < 30 mL/min./1.73 m2 (ICD-10 codes N18.4 and N18.5 - Severe alcohol abuse (ICD-10 codes F10.2 and K70.x). |
Country | Name | City | State |
---|---|---|---|
Denmark | Nordsjællands Hospital | Hillerød |
Lead Sponsor | Collaborator |
---|---|
Nordsjaellands Hospital | Rigshospitalet, Denmark, University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Total protein intake | Measured through 24-recall and calculated using MADlog (MADLOG, Denmark) in grams | 1 and 3 months after baseline | |
Other | Difference in protein requirement and protein intake | Intake measured through 24-recall and calculated using MADlog (MADLOG, Denmark) in grams adnd requirements is calculated as 1.5 g/kg/day. | 1 and 3 months after baseline | |
Other | Total energy intake | Measured through 24-recall and calculated using MADlog (MADLOG, Denmark) in kalories. | 1 and 3 months after baseline | |
Other | Difference in energy requirement and energy intake | Intake measured through 24-recall and calculated using MADlog (MADLOG, Denmark) in kalories. Requirements calculated as 30 kcal/kg/day if goal is weight maintenance and 45 kcal kg/day if goal is weight gain | 1 and 3 months after baseline | |
Other | Upper arm circumference | Measured using a measuring tape to the nearest 0.1 cm | 1 and 3 months after baseline | |
Other | Hip circumference | Measured using a measuring tape to the nearest 0.1 cm | 1 and 3 months after baseline | |
Other | Waist circumference | Measured using a measuring tape to the nearest 0.1 cm | 1 and 3 months after baseline | |
Other | Number of exacerbations | Obtained from patient files supplemented with self-reported information | 1 and 3 months after baseline | |
Other | Oxygen therapy | Self-reported. The participant is asked if he/she is currently using home oxygen. | 1 and 3 months after baseline | |
Other | Anxiety and depression | Measured using Hospital Anxiety and Depression Scale. The scale contains two subscales to evaluate risk of anxiety and depression. Each subscale contains 7 items with a total score from 0-21. Risk of anxiety and depression are based on a total score =8. | 1 and 3 months | |
Other | Physical activity (subjective) | Measured using the physical activity and vial signs questionnaire | 1 and 3 months after baseline | |
Other | Physical activity (objective) | Measured using accelerometers (Activity AX3, Newcastle, United Kingdom) | 7 days from 1- months follow-up and 7 days from 3 months follow-up | |
Primary | Health-related quality of life | Will be measured using the EQ-5D-5L | 1 and 3 months after baseline | |
Secondary | Weight | Measured using an electronic scale (TANITA DC 430 SMA, TANITA, Denmark) to the nearest 0.1 kg | 1 and 3 months after baseline | |
Secondary | Body mass index | Calculated as weight (kg)/height (m2) | 1 and 3 months after baseline | |
Secondary | Hand grip strength | Measured using handdynanometer | 1 and 3 months after baseline | |
Secondary | Lower body strength | Measured using 30 second stand chair test | 1 and 3 months after baseline | |
Secondary | Number of unplanned acute hospitalizations | Obtained from patient files | 1 and 3 months after baseline | |
Secondary | Number of days in hospital | Obtained from patient files | 1 and 3 months after baseline | |
Secondary | Number of acute unplanned visits to emergency ward (<6 hours) | Obtained from patient files | 1 and 3 months after baseline | |
Secondary | Number of contacts to outpatient clinic (visits and phone calls) | Obtained from patient files | up to 3 months after baseline | |
Secondary | Disease specific quality of life | Obtained using COPD Assessment test (CAT). CAT contains 8 items with a scoring range of 0-40. The total score indicate the impact level COPD has on the everyday life ranging from low to very high. A total score of 5 is referred to the upper limit of normal in healthy non-smokers, a total score <10 indicate low impact, 10-20 indicate medium impact, whereas >20 and >30 indicate high and very high impact, respectively. | 1 and 3 months after baseline | |
Secondary | Mortality | will be obtained from patient files | up to 3 months after baseline | |
Secondary | Fat-free mass | Measured using bioelectrical impedance analysis | 1 and 3 months after baseline | |
Secondary | Fat mass | Measured using bioelectrical impedance analysis | 1 and 3 months after baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|